The finnish diabetes risk score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk

Annals of Medicine

Volumn 43, Issue 6, 2011, Pages 413-417

  Musso, Giovanni ^a  

^a GRADENIGO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; INSULIN;

ABDOMINAL FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; FINNISH DIABETES RISK SCORE; FOLLOW UP; HUMAN; LIPID STORAGE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SCREENING TEST; ULTRASOUND; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FATTY LIVER; FEMALE; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 79960171759     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.579152     Document Type: Review

References (28)

1. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010 Nov 2 (Epub ahead of print).
2. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969-74.
3. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepa-tology. 2010;51:121-9.
4. Castera L. Non-invasive diagnosis of steatosis and fi brosis. Diabetes Metab. 2008;34:674-79.
5. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
6. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (Steato Test) for the prediction of liver steatosis. Comp Hepatol. 2005;4:10.
7. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology. 2010;10:98.
8. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool refl ecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42:503-8.
9. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-72.
10. Carvalho J, Barengo NC, Conceição R, Tuomilehto J, Santos R. The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. Ann Med. SANN-2010-0186.R2.
11. Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26:725-31. (Pubitemid 36929335)
12. Rathmann W, Martin S, Haastert B, Icks A, Holle R, Lowel H, et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey. 2000. Arch Intern Med. 2005;165:436-41. (Pubitemid 40280200)
13. Saaristo T, Peltonen M, Lindstrom J, Saarikoski L, Sundvall J, Eriksson JG, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2:67-72. (Pubitemid 40826998)
14. Franciosi M, Berardis G, De Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28:1187-94. (Pubitemid 40616633)
15. Silventoinen K, Pankow J, Lindstr ö m J, Jousilahti P, Hu G, Tuomilehto J. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005;12:451-58. (Pubitemid 44966789)
16. Bergmann A, Li J, Wang L, Schulze J, Bornstein SR, Schwarz PE. A simplifi ed Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res. 2007;39:677-82. (Pubitemid 47492652)
17. Lin JW, Chang YC, Li HY, Chien YF, Wu MY, Tsai RY, et al. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney disease in Taiwanese. Diabetes Care. 2009;32:2294-6.
18. Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011; 92:46-52.
19. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2010 Dec 6 (Epub ahead of print).
20. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2008;31:2056-61.
21. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F; Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gas-troenterol. 2010;10:56.
22. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537-44.
23. Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care. 2006;29:151-3. (Pubitemid 44033451)
24. Bozorgmanesh M, Hadaegh F, Azizi F. Diabetes prediction, lipid accumulation product, and adiposity measures; 6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis. 2010;9:45.
25. Bozorgmanesh M, Hadaegh F, Azizi F Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis. 2010;9:100.
26. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48:1-26.
27. Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastro-enterol. 2009;44:1064-70.
28. Musso G, Gambino R, Cassader M. The need for a three-focused approach to non-alcoholic fatty liver disease (NAFLD). Hepatology. 2011;53:1773.